CFTR and cystic fibrosis: The use of CRISPR-Cas9 editing to knockout CFTR in healthy human MDMs has been demonstrated previously and was shown to induce development of multiple known CF macrophage functional defects (including reduced bactericidal ability), strongly suggesting the CFTR-dependent nature of these impairments (70).